For anyone in Săcel looking to source CJC-1295, the first thing to know is that this compound moves through online research channels. This matters because CJC-1295 quality ranges widely across the market — from verified research-grade material to material with significant impurity issues — and the vendor controls every quality variable. What genuinely separates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Săcel researcher needs before placing a first order.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Săcel comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
The first step for any Săcel researcher sourcing CJC-1295 is finding vendors with verified community track records — commercial rankings reflect SEO budgets rather than product quality. The HPLC purity trace is the most important document in the COA: it should show a large primary peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be at or above 98%. Positive vendor signals beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. Store lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Săcel
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no pricing advantage justifies skipping this verification. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not a licensed human medication and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
